左西孟旦治疗脓毒性休克的研究进展  

Research Progress in the Treatment of Septic Shock with Levosimendan

作　　者：余杏锋 YU Xing-feng(Department of Critical Care Medicine,Fuqing Municipal Hospital,Fuqing Fujian 350300,China)

机构地区：[1]福清市医院重症医学科,福建福清350300

出　　处：《抗感染药学》2024年第6期555-558,共4页Anti-infection Pharmacy

摘　　要：脓毒性休克是指侵入血液循环的病原微生物及其毒素激活宿主的细胞和体液免疫系统,产生各种细胞因子和炎症介质,从而引起全身炎症反应综合征,并进一步作用于机体各个器官、系统,造成组织细胞破坏、代谢紊乱、功能障碍,甚至多器官功能障碍,最终导致以休克为突出表现的危重综合征。左西孟旦作为一种钙离子增敏剂,不仅能提高心肌收缩力且不增加细胞氧耗,还能扩张冠状动脉和全身血管,从而改善血流动力学。该文主要从脓毒性休克的流行病学特点和发病机制、左西孟旦的药理作用及其机制,以及左西孟旦在脓毒性休克中的应用和潜在风险等方面进行了综述,为左西孟旦的临床使用提供参考。Septic shock occurs when pathogenic microorganisms and their toxins invading the blood circulation activate the host's cellular and humoral immune systems,producing various cytokines and inflammatory mediators to cause systemic inflammatory response syndrome,and further act on various organs and systems,causing histiocytic destruction,metabolic disorders,dysfunction,and even multiple organ dysfunction,ultimately leading to a critical syndrome with shock as a prominent manifestation.Levosimendan,as a calcium ion sensitizer,can not only improve myocardial contractility without increasing cellular oxygen consumption,but also dilate coronary arteries and systemic blood vessels,thereby improving hemodynamics.In this article,the epidemiological characteristics and pathogenesis of septic shock,the pharmacological effects and mechanisms of levosimendan,and the application and potential risks of levosimendan in septic shock are mainly reviewed,to provide a reference for the clinical use of levosimendan.

关 键 词：左西孟旦 脓毒性休克 临床治疗 研究进展 

分 类 号：R631.4[医药卫生—外科学] R972[医药卫生—临床医学]